1
|
Doucet L, Cailleteau A, Vaugier L, Gourmelon C, Bureau M, Salaud C, Roualdes V, Samarut E, Aumont M, Zenatri M, Loussouarn D, Quillien V, Bocquet F, Payen-Gay L, Joubert D, Prieur A, Robert M, Frenel JS. Association between post-operative hPG 80 (circulating progastrin) detectable level and worse prognosis in glioblastoma. ESMO Open 2023; 8:101626. [PMID: 37713930 PMCID: PMC10594012 DOI: 10.1016/j.esmoop.2023.101626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 07/06/2023] [Accepted: 08/02/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG80, is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evaluated the prognostic value of plasma hPG80 in patients with isocitrate dehydrogenase-wild type glioblastoma after surgery. PATIENTS AND METHODS A multicentric retrospective study in glioblastoma patients treated with standard radio-chemotherapy was conducted. The hPG80 levels were measured in plasma EDTA samples collected after surgery with an ELISA DxPG80.lab kit (Biodena Care, Montpellier, France), which has a detection threshold of 1.2 pM. The relationship between post-operative hPG80 plasma levels, in combination with other known prognostic factors, and patients' progression-free survival (PFS) and overall survival (OS) was evaluated. RESULTS Sixty-nine patients were assessable. Plasma samples were collected after tumor biopsy (B), partial resection (PR), and complete resection (CR) for 22, 25, and 22 patients, respectively. At a median concentration of 5.37 pM (interquartile range 0.00-13.90 pM), hPG80 was detected in 48 (70%) patients (hPG80+). CR was associated with significant lower values of hPG80 levels: the median value was 0.7 versus 9.1 pM for PR (P = 0.02) and 8.3 pM for B (P = 0.004). The hPG80 detection rate was also significantly lower: 50% (CR) versus 72% (PR) versus 86% (B) (P = 0.005). The median follow-up was 39 months [22.4 months-not reached]. hPG80 post-operative detection was associated with numerically shorter PFS (6.4 versus 9.4 months, P = 0.13) and OS (14.5 versus 20.9 months, P = 0.11). In multivariate analysis, hPG80 was a prognostic factor for OS (P = 0.034). CONCLUSIONS Circulating hPG80 could serve as a new prognostic biomarker after surgery in patients with glioblastoma treated with radio-chemotherapy.
Collapse
Affiliation(s)
- L Doucet
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
| | - A Cailleteau
- Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - L Vaugier
- Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - C Gourmelon
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - M Bureau
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - C Salaud
- Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France
| | - V Roualdes
- Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France
| | - E Samarut
- Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France
| | - M Aumont
- Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - M Zenatri
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - D Loussouarn
- Department of Pathology, Centre Hospitalo-Universitaire, Nantes, France
| | - V Quillien
- Department of Biology, Centre Eugene Marquis, Rennes, France
| | - F Bocquet
- Data Factory & Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - L Payen-Gay
- Department of Biochemistry, Molecular Oncology and Transfer Unit, Cancer Institute of Hospices Civils De Lyon, Pierre Benite, France
| | | | | | - M Robert
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - J-S Frenel
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| |
Collapse
|
2
|
Ah-Thiane L, Rousseau C, Aumont M, Cailleteau A, Doré M, Mervoyer A, Vaugier L, Supiot S. The Sentinel Lymph Node in Treatment Planning: A Narrative Review of Lymph-Flow-Guided Radiotherapy. Cancers (Basel) 2023; 15:2736. [PMID: 37345071 DOI: 10.3390/cancers15102736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 05/09/2023] [Accepted: 05/11/2023] [Indexed: 06/23/2023] Open
Abstract
The sentinel lymph node technique is minimally invasive and used routinely by surgeons, reducing the need for morbid extensive lymph node dissections, which is a significant advantage for cancer staging and treatment decisions. The sentinel lymph node could also help radiation oncologists to identify tumor drainage for each of their patients, leading to a more personalized radiotherapy, instead of a probabilistic irradiation based on delineation atlases. The aim is both to avoid recurrence in unexpected areas and to limit the volume of irradiated healthy tissues. The aim of our study is to evaluate the impact of sentinel lymph node mapping for radiation oncologists. This concept, relying on sentinel lymph node mapping for treatment planning, is known as lymph-flow-guided radiotherapy. We present an up-to-date narrative literature review showing the potential applications of the sentinel lymph node technique for radiotherapy, as well as the limits that need to be addressed before its routine usage.
Collapse
Affiliation(s)
- Loic Ah-Thiane
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
| | - Caroline Rousseau
- Department of Nuclear Medicine, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
- CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Nantes University, 44000 Nantes, France
| | - Maud Aumont
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
| | - Axel Cailleteau
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
| | - Mélanie Doré
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
| | - Augustin Mervoyer
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
| | - Loig Vaugier
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
| | - Stéphane Supiot
- Department of Radiotherapy, ICO René Gauducheau, Boulevard Jacques Monod, 44800 St-Herblain, France
- CRCI2NA, Inserm UMR 1232, CNRS ERL 6001, Nantes University, 44000 Nantes, France
| |
Collapse
|
3
|
Doucet L, Cailleteau A, Vaugier L, Gourmelon C, Bureau M, Salaud C, Roualdes V, Samarut E, Aumont M, Zenatri M, Loussouarn D, Quillien V, Bocquet F, Payen-Gay L, Mahi Y, Prieur A, Robert M, Frenel JS. Prognostic value of hPG 80 (circulating progastrin) in IDH-wild type glioblastoma treated with radio-chemotherapy. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.2049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2049 Background: hPG80 (circulating progastrin) is a protein secreted by many cancer types, playing a role in tumorigenesis by regulating cancer stem cells, angiogenesis, proliferation/differentiation and decreasing apoptosis. hPG80 is detectable in plasma of cancer patients and previous studies have shown its prognostic role in various cancers. Given the lack of circulating biomarker in glioblastoma, we evaluated the prognostic value of plasma hPG80 in patients with IDH wild type glioblastoma Methods: This multicentric retrospective study included IDHwt glioblastoma patients treated with standard radio-chemotherapy. The ELISA DxPG80.lab kit (Biodena Care, Lausanne, Switzerland) was used to measure hPG80 levels after surgery with a detection threshold of 1 pM in all plasma EDTA samples according to the manufacturer’s instruction. The prognostic impact of hPG80 was evaluated on patient’s progression-free survival (PFS) and overall survival (OS). Results: We included 70 patients (38 males /32 women) with a median age of 64 years (Range 19 - 84). Karnofsky index was > 70% in 52 (91%) of 57 evaluable patients. Tumor biopsy (B), partial resection (PR), complete resection (CR) were performed in 22, 25 and 23 patients respectively. MGMT promotor was methylated in 22 (40%) of the 55 evaluable patients. After surgery, hPG80 was detected in 48 (69%) patients (hPG80+) with a median concentration of 9.52 pM (IQR 5.21 - 21.20). Complete surgery was associated with undetectable levels of hPG80 (52% (CR) vs 28% (PR) vs 14% (B), p = 0.006) and lower concentration if hPG80+ (CR: 5.8 pM [IQR 1.92 - 11.38] vs PR: 12.84 pM [IQR 8.09 - 37.09]; p = 0.04 vs B: 9.86 pM [IQR 4.66 - 21.63]; p = 0.16). With a median follow-up of 39 months (22.4-NR), 86% of patients had progressed and 70% had died. In univariate analysis, hPG80 positivity was associated with PFS (5.6m vs 8.5m, p = 0.053) and OS (14.5 vs 22m, p = 0.04) in hPG80+ vs hPG80- patients respectively. hPG80+ patients with complete surgery had worse median OS than hPG80- patients (14.5 vs 22.0 m; p = 0.051 respectively. Cox proportional hazards model did not fit for covariate analysis. Conclusions: Our findings show that hPG80 could serve as a new circulating prognostic biomarker in IDHwt glioblastoma patients treated with radio-chemotherapy. Further explorations are ongoing in larger cohorts including longitudinal evaluation during the course of the disease.
Collapse
Affiliation(s)
- Ludovic Doucet
- Institut de Cancerologie de l'Ouest, Medical Oncology, Saint-Herblain, France
| | - Axel Cailleteau
- Institut de Cancerologie de l'Ouest, Medical Oncology, Saint-Herblain, France
| | - Loig Vaugier
- Institut de Cancerologie de l'Ouest, Radiation Therapy Department, Saint-Herblain, France
| | - Carole Gourmelon
- Institut de Cancerologie de l'Ouest, Medical Oncology, Saint-Herblain, France
| | - Mathilde Bureau
- Institut de Cancerologie de l'Ouest, Medical Oncology, Saint-Herblain, France
| | - Celine Salaud
- CHU Nantes, Neurosurgery Department, Saint-Herblain, France
| | | | | | - Maud Aumont
- Institut de Cancerologie de l'Ouest, Radiation Therapy Department, Saint-Herblain, France
| | - Morgan Zenatri
- Institut de Cancerologie de l'Ouest, Medical Oncology, Saint-Herblain, France
| | | | | | - Francois Bocquet
- Institut de Cancerologie Ouest, Data Factory & Analytics, Nantes, France
| | - Lea Payen-Gay
- Biochemistry Department, Molecular Oncology and Transfer Unit, CIRCAN Program Coordinator, Cancer Institute of Hospices Civils De Lyon, Pierre Benite, France
| | | | | | - Marie Robert
- Institut de Cancerologie de l’Ouest, Medical Oncology, Saint Herblain, France
| | | |
Collapse
|
4
|
Vaugier L, Ah-Thiane L, Aumont M, Jouglar E, Campone M, Colliard C, Doucet L, Frenel JS, Gourmelon C, Robert M, Martin SA, Riem T, Roualdes V, Campion L, Mervoyer A. Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. Sci Rep 2021; 11:22057. [PMID: 34764361 PMCID: PMC8586368 DOI: 10.1038/s41598-021-01537-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 10/29/2021] [Indexed: 11/09/2022] Open
Abstract
Glioblastoma (GBM) is frequent in elderly patients, but their frailty provokes debate regarding optimal treatment in general, and the standard 6-week chemoradiation (CRT) in particular, although this is the mainstay for younger patients. All patients with newly diagnosed GBM and age ≥ 70 who were referred to our institution for 6-week CRT were reviewed from 2004 to 2018. MGMT status was not available for treatment decision at that time. The primary endpoint was overall survival (OS). Secondary outcomes were progression-free survival (PFS), early adverse neurological events without neurological progression ≤ 1 month after CRT and temozolomide hematologic toxicity assessed by CTCAE v5. 128 patients were included. The median age was 74.1 (IQR: 72-77). 15% of patients were ≥ 80 years. 62.5% and 37.5% of patients fulfilled the criteria for RPA class I-II and III-IV, respectively. 81% of patients received the entire CRT and 28% completed the maintenance temozolomide. With median follow-up of 11.7 months (IQR: 6.5-17.5), median OS was 11.7 months (CI 95%: 10-13 months). Median PFS was 9.5 months (CI 95%: 9-10.5 months). 8% of patients experienced grade ≥ 3 hematologic events. 52.5% of patients without neurological progression had early adverse neurological events. Post-operative neurological disabilities and age ≥ 80 were not associated with worsened outcomes. 6-week chemoradiation was feasible for "real-life" elderly patients diagnosed with glioblastoma, even in the case of post-operative neurological disabilities. Old does not necessarily mean worse.
Collapse
Affiliation(s)
- Loïg Vaugier
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest (ICO), Boulevard J. Monod, 44805, Nantes-Saint-Herblain, France.
| | - Loïc Ah-Thiane
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest (ICO), Boulevard J. Monod, 44805, Nantes-Saint-Herblain, France
| | - Maud Aumont
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest (ICO), Boulevard J. Monod, 44805, Nantes-Saint-Herblain, France
| | - Emmanuel Jouglar
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest (ICO), Boulevard J. Monod, 44805, Nantes-Saint-Herblain, France
| | - Mario Campone
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes-Saint-Herblain, France
| | - Camille Colliard
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes-Saint-Herblain, France
| | - Ludovic Doucet
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes-Saint-Herblain, France
| | - Jean-Sébastien Frenel
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes-Saint-Herblain, France
| | - Carole Gourmelon
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes-Saint-Herblain, France
| | - Marie Robert
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes-Saint-Herblain, France
| | - Stéphane-André Martin
- Department of Neurosurgery, Centre Hospitalo-Universitaire (CHU), Nantes-Saint Herblain, France
| | - Tanguy Riem
- Department of Neurosurgery, Centre Hospitalo-Universitaire (CHU), Nantes-Saint Herblain, France
| | - Vincent Roualdes
- Department of Neurosurgery, Centre Hospitalo-Universitaire (CHU), Nantes-Saint Herblain, France
| | - Loïc Campion
- Department of Biostatistics, Institut de Cancérologie de l'Ouest, St-Herblain, France.,Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), UMR 1232 Inserm-6299 CNRS, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France
| | - Augustin Mervoyer
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest (ICO), Boulevard J. Monod, 44805, Nantes-Saint-Herblain, France
| |
Collapse
|
5
|
Moreau-Bachelard C, Campion L, Robert M, Kerdraon O, Renaudeau C, Aumont M, Classe JM, Campone M, Frénel JS. Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers (Basel) 2020; 12:E3725. [PMID: 33322473 PMCID: PMC7763581 DOI: 10.3390/cancers12123725] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 12/03/2020] [Accepted: 12/10/2020] [Indexed: 11/17/2022] Open
Abstract
Background: The selection of women with hormone receptor-positive (HR+) early breast cancer (EBC) at high risk of relapse after five years (yrs.) of adjuvant aromatase inhibitors (AIs) is crucial, as the benefit of extending AIs is counterbalanced by toxicity. We developed a clinicopathological tool to estimate the residual risk of relapse after five years of adjuvant AIs. Methods: The Institut de Cancérologie de l'Ouest (ICO) database was used to determine a prognostic score of post-five-year AI relapse. Cox regression models estimated our score's prognostic performance. Results: In total, 1105 women were included. Median follow-up was 44 months (IQR = 21-70) post-AI treatment. From the Cox models, we designed a dichotomous prognostic score including the number of macrometastases, age (>70 yrs. vs. ≤70 yrs.), tumor size (≥T2 vs. not), and mitotic activity (≥2 vs. not). Overall, 77.5% of patients were classified as being at low risk and 22.5% at high risk of late recurrence. Low-risk patients had a five- to ten-year local or distant recurrence risk of 7.6% (95% CI, 5.4% to 10.6%) as compared with 26.9% (95% CI, 19.9% to 35.7%) for the high-risk roup. Conclusion: In this study, we developed a simple tool to identify women at high risk of relapse despite completing five years of AIs.
Collapse
Affiliation(s)
- Camille Moreau-Bachelard
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France; (C.M.-B.); (M.R.); (M.C.)
| | - Loïc Campion
- Department of Biometrics, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France;
- CRCINA, University of Nantes, INSERM UMR1232, CNRS-ERL6001, 44000 Nantes, France
| | - Marie Robert
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France; (C.M.-B.); (M.R.); (M.C.)
| | - Olivier Kerdraon
- Department of Pathology, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France;
| | - Céline Renaudeau
- Department of Surgery, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France; (C.R.); (J.-M.C.)
| | - Maud Aumont
- Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France;
| | - Jean-Marc Classe
- Department of Surgery, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France; (C.R.); (J.-M.C.)
| | - Mario Campone
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France; (C.M.-B.); (M.R.); (M.C.)
| | - Jean-Sébastien Frénel
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Boulevard Professeur Jacques Monod, 44800 Saint-Herblain, France; (C.M.-B.); (M.R.); (M.C.)
| |
Collapse
|
6
|
Frenel JS, Cartron PF, Gourmelon C, Campion L, Aumont M, Augereau P, Ducray F, Loussouarn D, Lallier L, Robert M, Campone M. 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
7
|
Frappart F, Biancamaria S, Normandin C, Blarel F, Bourrel L, Aumont M, Azemar P, Vu PL, Le Toan T, Lubac B, Darrozes J. Influence of recent climatic events on the surface water storage of the Tonle Sap Lake. Sci Total Environ 2018; 636:1520-1533. [PMID: 29913613 DOI: 10.1016/j.scitotenv.2018.04.326] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 04/23/2018] [Accepted: 04/24/2018] [Indexed: 06/08/2023]
Abstract
Lakes and reservoirs have been identified as sentinels of climate change. Tonle Sap is the largest lake in both the Mekong Basin and Southeast Asia and because of the importance of its ecosystem, it is has been described as the "heart of the lower Mekong". Its seasonal cycle depends on the annual flood pulse governed by the flow of the Mekong River. This study provides an impact analysis of recent climatic events from El Niño 1997/1998 to El Niño 2015/2016 on surface storage variations in the Tonle Sap watershed determined by combining remotely sensed observations, multispectral images and radar altimetry from 1993 to 2017. The Lake's surface water volume variations are highly correlated with rainy season rainfall in the whole Mekong River Basin (R = 0.84) at interannual time-scale. Extreme droughts and floods can be observed when precipitation deficit and excess is recorded in both the Tonle Sap watershed and the Mekong River Basin during moderate to very strong El Niño/La Niña events (R = -0.70) enhanced by the Pacific Decadal Oscillation (R = -0.68). Indian and Western North Pacific Monsoons were identified as having almost equal influence. Below normal vegetation activity was observed during the first semester of 2016 due to the extreme drought in 2015.
Collapse
Affiliation(s)
- F Frappart
- Géosciences Environnement Toulouse (GET), UMR 5563, CNRS/IRD/Université de Toulouse, OMP-GRGS, 14 Avenue Edouard Belin, 31400 Toulouse, France; LEGOS, Université de Toulouse, CNES, CNRS, IRD, UPS - 14 avenue Edouard Belin, 31400 Toulouse, France.
| | - S Biancamaria
- LEGOS, Université de Toulouse, CNES, CNRS, IRD, UPS - 14 avenue Edouard Belin, 31400 Toulouse, France
| | - C Normandin
- Environnement et Paléo-Environnement Océaniques et Continentaux (EPOC), UMR 5805, CNRS/Université de Bordeaux, Allée Geoffroy Saint-Hilaire, 33615 Pessac, France
| | - F Blarel
- LEGOS, Université de Toulouse, CNES, CNRS, IRD, UPS - 14 avenue Edouard Belin, 31400 Toulouse, France
| | - L Bourrel
- Géosciences Environnement Toulouse (GET), UMR 5563, CNRS/IRD/Université de Toulouse, OMP-GRGS, 14 Avenue Edouard Belin, 31400 Toulouse, France
| | - M Aumont
- LEGOS, Université de Toulouse, CNES, CNRS, IRD, UPS - 14 avenue Edouard Belin, 31400 Toulouse, France
| | - P Azemar
- LEGOS, Université de Toulouse, CNES, CNRS, IRD, UPS - 14 avenue Edouard Belin, 31400 Toulouse, France
| | - P-L Vu
- Géosciences Environnement Toulouse (GET), UMR 5563, CNRS/IRD/Université de Toulouse, OMP-GRGS, 14 Avenue Edouard Belin, 31400 Toulouse, France
| | - T Le Toan
- Centre d'Etudes Spatiales de la Biosphère (CESBIO), UMR 5126,CNRS/CNES/IRD/Université de Toulouse, 13 Avenue du Colonel Roche, 31400 Toulouse, France
| | - B Lubac
- Environnement et Paléo-Environnement Océaniques et Continentaux (EPOC), UMR 5805, CNRS/Université de Bordeaux, Allée Geoffroy Saint-Hilaire, 33615 Pessac, France
| | - J Darrozes
- Géosciences Environnement Toulouse (GET), UMR 5563, CNRS/IRD/Université de Toulouse, OMP-GRGS, 14 Avenue Edouard Belin, 31400 Toulouse, France
| |
Collapse
|
8
|
Aumont M. [What is the role of intraoperative radiotherapy in breast cancer treatment?]. Cancer Radiother 2016; 20:583-6. [PMID: 27614504 DOI: 10.1016/j.canrad.2016.07.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 07/08/2016] [Indexed: 10/21/2022]
Abstract
Breast-conserving surgery followed by whole breast postoperative irradiation is considered to be the current standard treatment for patients with early stage breast cancer. It allows an excellent local tumour control with 6% of local recurrence. Over the last years, partial breast radiotherapy has been developed to reduce treatment volume and duration. Intraoperative radiotherapy is one of the techniques. It offers an excellent delineation of the tumour bed and high normal tissue sparing. This purpose of this review is to describe the different intraoperative radiotherapy techniques available, to assess their potential clinical efficiency and tolerance, the recommendations for new practice with a selected population of patients and for future research.
Collapse
Affiliation(s)
- M Aumont
- Département de radiothérapie, institut de cancérologie de l'Ouest, boulevard Jacques-Monod, 44085 Saint-Herblain, France.
| |
Collapse
|
9
|
Doutriaux-Dumoulin I, Aumont M. La validation d’un traitement chirurgical en RCP et la gestion des situations inhabituelles ne satisfaisant pas à tous les critères requis : place de l’imagerie. Imagerie de la Femme 2015. [DOI: 10.1016/j.femme.2015.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients. Clin Cancer Res 2015; 21:2530-7. [PMID: 25724520 DOI: 10.1158/1078-0432.ccr-14-2368] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Accepted: 01/11/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcinoma limited to the pelvis. EXPERIMENTAL DESIGN This randomized phase II trial enrolled 78 FIGO stage IB2-IIIB cervical cancer patients to either cisplatin-based radiochemotherapy alone (arm B, n = 38) or conjointly with a 6-week course of weekly cetuximab (arm A, n = 40). Brachytherapy was given to the pelvic mass. Primary endpoint was disease-free survival (DFS) at 2 years. EGFR expression and targeted sequencing were performed in 54 of 78 patients. RESULTS Cetuximab over a 6-week period did not improve DFS at 24 months. At 31 months median follow-up, DFS was not significantly different (P = 0.18). Complete response at 4 to 6 months was strongly predictive for excellent DFS (log-rank test; P < 0.001). PIK3CA, KRAS, and STK11 mutations were observed in 22%, 4%, and 2% of patients, respectively. No tumor with a PI3K pathway mutation showed complete response (0/8 in arm A and 0/6 in arm B), whereas 14 of 52 (27%) tumors without mutations did (P = 0.021). PI3K pathway-mutated tumors showed a trend toward poorer DFS (P = 0.06) following cetuximab (8/22) as compared with those following standard treatment only (6/18). CONCLUSIONS Similar to patients with head and neck cancer, patients with cervical cancer showed no gain in DFS at 2 years following a combined treatment of cetuximab with radiochemotherapy. Although treatment tolerance and compliance were satisfactory, it remains to be demonstrated whether maintenance therapy with cetuximab could be beneficial in selected patient groups.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Michel Fabbro
- Centre Val d'Aurelle - Paul Lamarque, Montpellier, France
| | - Christine Kerr
- Centre Val d'Aurelle - Paul Lamarque, Montpellier, France
| | | | | | | | | | | | | | | | | | | | - Maud Aumont
- Institut de cancérologie de l'Ouest, René Gauducheau, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Noel G, Huchet A, Feuvret L, Maire JP, Verrelle P, Le Rhun E, Aumont M, Thillays F, Sunyach MP, Henzen C, Missohou F, de Crevoisier R, Bondiau PY, Collin P, Durando X, Truc G, Kerr C, Bernier V, Clavier JB, Atlani D, D'Hombres A, Vinchon-Petit S, Lagrange JL, Taillandier L. Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol 2012; 109:167-75. [PMID: 22660920 DOI: 10.1007/s11060-012-0883-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2011] [Accepted: 04/16/2012] [Indexed: 11/28/2022]
Abstract
Purpose of this study was to determine the effect of waiting time for radiotherapy on overall survival of patients with glioblastoma treated in the EORTC-NCIC trial at 18 centers in France. A total of 400 adult patients with glioblastoma who were treated between January 1, 2006 and December 31, 2006 were included. There were 282 patients with "minimum criteria" according to the EORTC-NCIC trial: (i) concurrent chemotherapy with temozolomide; and (ii) age between 18 and 70 years old. Among these patients, 229 were treated with adjuvant temozolomide and were classified as "maximal criteria". One-hundred and eighteen patients were in the "without minimal criteria" group. Waiting time from the first symptom (FS-RT), pathology diagnosis (P-RT), multidisciplinary meeting (MM-RT), surgery (S-RT), and CT scan for delineation (CT-RT) until the start of radiotherapy were recorded. Median follow-up for all patients was 327 days. Overall, median FS-RT, P-RT, MM-RT, CT-RT, and S-RT times were 77, 36, 32, 12, and 41 days, respectively. Median, and 12 and 24-month overall survival were 409 days, and 56.3 ± 2.1 % and 27.6 ± 2.6 %, respectively. Univariate analysis failed to reveal a difference in survival, irrespective of the delay. In multivariate analysis, independent favorable prognostic factors for overall survival were age (p ≤ 0.0001) and type of surgery (p = 0.0006). In this large series treated during the EORTC-NCIC protocol period, waiting time until radiotherapy did not seem to affect patient outcome.
Collapse
Affiliation(s)
- Georges Noel
- CLCC Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Toulgoat F, Arrigoni PP, Loussouarn D, Leux C, Frenel JS, Denis MG, Le loupp AG, Aumont M, Campone M, Martin S, Desal H. Relationship between IDH1 mutation status and magnetic resonance imaging features in WHO grade II and III oligodendroglial tumors. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.2082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2082 Background: In gliomas, relationship between radiological characteristics and several biomarkers was the subject of numerous publications. Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified recently to play a key role in these tumors occuring in up to 75% of low-grade diffuse (WHO grade II) and anaplastic (WHO grade III) astrocytic, oligodendroglial and mixed oligodendroglial neoplasms. However, the correlation with magnetic resonance imaging (MRI) features has been little studied. Methods: Patients treated for WHO grade II and III oligodendroglial tumors between 2005 and 2011 were retrospectively identified. Each case has been reviewed by the same neuropathologist. IDH1 and IDH2 mutations were available. Preoperative MRI, including T1 weighted, T2 weighted, T1 contrast enhanced, FLAIR, T2* weighted, diffusion weighted (ADC ratio), perfusion weighted (CBV ratio) and MR spectroscopy, were analyzed by two radiologists blinded from molecular data. Logistic regression analysis and Fisher’s test were used to develop predictive models of genetic profile from imaging. Results: Sixty eight patients, WHO grade II (n= 37) and grade III (n=31) patients were identified. Mean age at diagnosis was 46 years; ratio male/female was 40/28. IDH1 mutations were identified in 42 patients (62 %), IDH2 in 4 patients (6 %). Analysis of tumor location, size, borders, morphological aspect, and signal did not shown any significant difference between IDH1 mutated group and IDH1 non mutated group neither in grade II nor in grade III oligodendroglial tumors. In the same way, MR spectroscopy (Choline/NAA ratio and detection of lipid and lactate) was not relevant to discern the two groups. As well, ADC ratio (1,5 versus 1,4; p=0,35) and CBV ratio (3,4 versus 4,2; p= 0,46) did not reveal any difference between mutated group and non mutated group. Conclusions: In our study, IDH1 mutations were not correlated with MRI features available during routine MRI. Nevertheless, recent studies suggest the ability of MR spectroscopy to detect 2-hydroxyglutarate as an MRI marker of IDH1 mutated tumors, which encourage carrying on research in molecular imaging.
Collapse
Affiliation(s)
| | | | | | - Christophe Leux
- Service d'Epidemiologie et de Biostatistiques, Nantes, France
| | | | | | | | - Maud Aumont
- Centre René Gauducheau, Saint-Herblain, France
| | - Mario Campone
- Institut de Cancérologie de l'Ouest - René Gauducheau, Centre de Recherche en Cancérologie, Saint Herblain-Nantes, France
| | | | | |
Collapse
|
13
|
Loussouarn D, Le Loupp AG, Frenel JS, Leclair F, Von Deimling A, Aumont M, Martin S, Campone M, Denis MG. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 2012; 40:2058-62. [PMID: 22447191 DOI: 10.3892/ijo.2012.1404] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Accepted: 02/13/2012] [Indexed: 11/05/2022] Open
Abstract
Previous studies have identified mutations of the isocitrate dehydrogenase 1 (IDH1) gene in more than 70% of World Health Organization (WHO) grade II and III gliomas. The most frequent mutation leads to a specific amino acid change from arginine to histidine at codon 132 (c.395G>A, p.R132H). IDH1 mutated tumors have a better prognosis than IDH1 non-mutated tumors. The aim of our study was to evaluate and compare the methods of mIDH1 R132H immunohistochemistry, allele-specific PCR and DNA sequencing for determination of IDH1 status. We performed a retrospective study of 91 patients with WHO grade II (n=43) and III (n=48) oligodendrogliomas. A fragment of exon 4 spanning the sequence encoding the catalytic domain of IDH1, including codon 132, was amplified and sequenced using standard conditions. Allele-specific amplification was performed using two forward primers with variations in their 3' nucleotides such that each was specific for the wild-type or the mutated variant, and one reverse primer. Immunohistochemistry was performed with mouse monoclonal mIDH1 R132H. DNA was extracted from FFPE sections following macrodissection. IDH1 mutations were found in 55/90 patients (61.1%) by direct sequencing. R132H mutations were found in 47/55 patients (85.4%). The results of the allele-specific PCR positively correlated with those from DNA sequencing. Other mutations (p.R132C, p.R132S and pR132G) were found by DNA sequencing in 3, 3 and 2 tumors, respectively (8/55 patients, 14.6%). mIDH1 R132H immunostaining was found in the 47 patients presenting the R132H mutation (sensitivity 47/47, 100% for this mutation). None of the tumors presenting a wild-type IDH1 gene were stained (specificity 35/35, 100%). Our results demonstrate that immunohistochemistry using the mIDH1 R132H antibody and allele-specific amplification are highly sensitive techniques to detect the most frequent mutation of the IDH1 gene.
Collapse
|
14
|
Le Blanc-Onfroy M, Aumont M, Dejode M, Dravet F, Lisbona A, Mahé MA. Expérience nantaise préliminaire de l’irradiation peropératoire exclusive dans les petits cancers du sein. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
15
|
Noel G, Maire J, Huchet A, Le Rhun E, Feuvret L, Aumont M, Sunyach M, Henzen C, de Crevoisier R, Taillandier L. Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients with Glioblastoma: A French Retrospective Analysis of Patients Treated with Concomitant Temozolomide and Radiotherapy. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Loussouarn D, Le Loupp A, Frenel J, Leclair F, Von Deimling A, Aumont M, Martin S, Campone M, Denis MG. Detection of IDH1 mutations in a series of 91 oligodendrogliomas: Comparison of immunohistochemistry, DNA sequencing, and allele-specific PCR. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Frenel J, Leux C, Loussouarn D, Le Loupp A, Leclair F, Von Deimling A, Aumont M, Martin S, Denis MG, Campone M. Predictive value of IDH1 mutation assessed by immunohistochemistry and DNA sequencing in WHO grade 3 oligodendrogliomas. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Sunyach M, Padovani L, Carrie C, Alapetite C, Aumont M. Adult Medulloblastoma: What about the Neurocognitive Toxicity after Craniospinal Radiation? Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.692] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Aumont M, Mahe MA, Prevost B, Sunyach MP, Peiffert D, Maingon P, Thomas L, Begue M, Willaume D, Lerouge D, Campion L. Exclusive high dose rate brachytherapy (HDR-BT) for early stage non-small cell lung carcinoma: Results of a retrospective study in 226 patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7688 Objective: To evaluate efficacy and toxicity of HDR BT in non operable endobronchial carcinoma from a retrospective multicentric study. Patients and Methods: Criteria for selection: non small cell carcinoma accessible to fiberoptic bronchoscopy, no extrabronchial extension on CT, contraindication to surgery and external radiation therapy (ERT). Statistical analysis: survival curves calculated with the Kaplan-Meier method and compared with the Logrank test; Cox model to evaluate in uni and multivariate analysis the impact on survival and complications of these parameters: location of tumor: lobar or segmental vs main stem bronchus, previous ERT vs no, total dose:= 30 Gy vs less, dose per fraction:= 5 Gy vs more, number of catheter(s):1 vs = 2. Results: Between 1991 and 2006, 226 patients from 9 radiotherapy departments were included. Main characteristics of tumors: squamous-cell histology: 96%, stage Tis: 60, T1: 153, T2: 9, Tx 4; lobar or segmental location: 91%. 51 patients (22.5%) had received ERT for previous lung cancer(s). Characteristics of HDR BT were: total dose = 30 Gy: 70%, dose per fraction = 5 Gy: 66%, 1 catheter: 46%. Dose was prescribed at 1 cm from the radius. Mean follow-up was 30.4 months (9- 116). Histologic evaluation was performed at 3 months in 137 patients. 92% had a complete response. 128 patients were died: intercurrent disease 45, local failure 35, complications 13. Two and 5-year survival: overall: 57%, 29%; specific (death of lung cancer) 81%, 56%; local- relapse free (LRF) 68%, 50%. Toxicity included 1.3% pneumothorax, hemoptysis 6.6% (5% fatal), bronchitis 20%. In univariate analysis: overall, specific and LRF survival were better for lobar or segmental location vs main stem bronchus (p=0.0001), overall and specific survival were higher with no previous ERT (p=0.006). In multivariate analysis, lobar or segmental location was associated with improved overall (p=0.0001) and LRF (p=0.003) survival. LRF survival was better in patients treated with = 2 catheters (p=0.007). No factor influence frequency of complications. Conclusion: This large retrospective study confirmed that HDRBT is efficient and safe in medically inoperable patients particulary with lobar or segmental endobronchial carcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Aumont
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - M. A. Mahe
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - B. Prevost
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - M. P. Sunyach
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - D. Peiffert
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - P. Maingon
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - L. Thomas
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - M. Begue
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - D. Willaume
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - D. Lerouge
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| | - L. Campion
- Centre Rene Gauducheau, St. Herblain, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Alexis Vautrin, Nancy, France; Centre Georges-Francois Leclerc, Dijon, France; Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Francois Baclesse, Caen, France
| |
Collapse
|
20
|
Cutilletta AF, Aumont M, Nag A, Zak R. Separation of muscle and non-muscle cells from adult rat myocardium: an application to the study of RNA polymerase. J Mol Cell Cardiol 1977; 9:399-407. [PMID: 875046 DOI: 10.1016/s0022-2828(77)80006-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
21
|
P. P, Gros A, Bour H, Gueron G, Aumont M. Vieillesse et longevite dans la societe de demain. Population (French Edition) 1969. [DOI: 10.2307/1528073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
22
|
Aumont M, Lanterno MT. [Social service of the infantile medical clinic]. Alger Medicale 1957; 61:631-6 passim. [PMID: 13458037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
|